v3.22.2

BALANCE SHEETS - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 39,393	$ 18,570
Accounts receivable, net of allowance of $75,000 and $13,203, respectively	1,213	54,164
Inventories	393	5,418
Prepaid expenses and other current assets	10,000	10,000
Total current assets	50,999	88,152
Total assets	50,999	88,152
Current liabilities:
Accounts payable	1,373,413	1,282,010
Accrued expenses	1,951,390	1,511,281
Advances - related parties	951,432	861,432
Deferred revenue, current portion	3,000	3,000
Deposits	465,286	465,286
Notes payable - related parties	3,144,200	2,721,478
Notes payable, current portion, net of debt discount of $10,052 and $9,610, respectively	2,557,881	2,562,149
Promissory note payable	1,397,762	1,397,762
Convertible notes payable, net of debt discount of $241,589 and $1,874, respectively	194,411	43,126
Total current liabilities	12,038,775	10,847,524
Long-term liabilities:
Deferred revenue	56,500	59,500
Notes payable, net of debt discount of $21,575 and $31,627, respectively	722,060	760,420
Total long-term liabilities	778,560	819,920
Total liabilities	12,817,335	11,667,444
Commitments and contingencies (See Note 12)
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, -0- issued and outstanding	0	0
Common stock, par value $0.001; 2,000,000,000 shares authorized, 503,525,051 and 435,560,794 shares issued and outstanding, respectively	503,525	435,561
Additional paid-in capital	126,532,063	124,499,655
Accumulated deficit	(139,801,924)	(136,514,508)
Total stockholders' deficit	(12,766,336)	(11,579,292)
Total liabilities and stockholders' deficit	$ 50,999	$ 88,152

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

U.S. Stem Cell, Inc. 10-K/A